State Board of Administration of Florida Retirement System raised its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) by 386.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 197,917 shares of the biotechnology company’s stock after purchasing an additional 157,212 shares during the quarter. State Board of Administration of Florida Retirement System owned 0.17% of Heron Therapeutics worth $495,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also bought and sold shares of HRTX. Douglas Lane & Associates LLC bought a new position in Heron Therapeutics during the fourth quarter valued at $25,000. Venturi Wealth Management LLC bought a new stake in shares of Heron Therapeutics in the 4th quarter worth about $26,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Heron Therapeutics by 51.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,738 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 5,024 shares during the last quarter. Diversified Trust Co bought a new stake in shares of Heron Therapeutics in the 4th quarter worth about $47,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Heron Therapeutics in the 1st quarter worth about $48,000.
Analysts Set New Price Targets
HRTX has been the subject of several analyst reports. Evercore ISI lowered their target price on shares of Heron Therapeutics from $15.00 to $10.00 and set an “outperform” rating for the company in a report on Friday, March 24th. Needham & Company LLC restated a “buy” rating and issued a $7.00 target price on shares of Heron Therapeutics in a report on Friday, April 21st. Finally, StockNews.com initiated coverage on shares of Heron Therapeutics in a report on Thursday. They issued a “hold” rating for the company.
Heron Therapeutics Trading Up 8.3 %
Heron Therapeutics (NASDAQ:HRTX – Get Rating) last announced its quarterly earnings data on Thursday, March 23rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.08. Heron Therapeutics had a negative net margin of 132.57% and a negative return on equity of 21,127.62%. The company had revenue of $30.00 million during the quarter, compared to analyst estimates of $27.24 million. During the same quarter last year, the business posted ($0.54) EPS. The firm’s revenue for the quarter was up 44.9% on a year-over-year basis. On average, research analysts expect that Heron Therapeutics, Inc. will post -0.9 EPS for the current year.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
- Get a free copy of the StockNews.com research report on Heron Therapeutics (HRTX)
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
- Foot Locker And The Ebbing Tide Of Discretionary Spending
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.